Veeva Systems Comments on Legal Action Against IQVIA

Pharmaceutical Investing

Veeva Systems issues a statement in regards to its antitrust legal action against IQVIA, which received an update recently.

Veeva Systems (NYSE:VEEV) touts support from consumers in its antitrust legal action against IQVIA (NYSE:IQV).

As quoted in the press release:

After three years of trying to work with IQVIA in good faith toward a resolution regarding Veeva’s master data management software to no avail, Veeva filed its first antitrust lawsuit in 2017 to end IQVIA’s long history of anti-competitive behavior. IQVIA’s motion to dismiss that case failed and fact discovery is now substantially complete. Trial is expected to take place in late 2021.

Veeva aims to remove the restrictions IQVIA places on companies. Successful judgments would forever prevent IQVIA from blocking customer choice. Veeva is committed to achieving a successful resolution for the industry that ends IQVIA’s long track record of monopoly abuse, despite IQVIA’s baseless claims and motions attempting to prevent the case from reaching trial.

“IQVIA is harming the life sciences industry by blocking third-party data agreements that ultimately slow getting treatments to the patients that need them,” said Peter Gassner, founder and CEO of Veeva. “We have built a very strong case against IQVIA and the evidence continues to mount. We will keep doing what’s best for our customers despite attempts by IQVIA to keep this case from being heard. Thanks to the many biopharmaceutical companies from across the industry who testified to IQVIA’s abusive monopolistic practices.”

Click here to read the full press release.

The Conversation (0)
×